Comparative Pharmacology
Head-to-head clinical analysis: FLAXEDIL versus NIMBEX PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLAXEDIL versus NIMBEX PRESERVATIVE FREE.
FLAXEDIL vs NIMBEX PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FLAXEDIL (gallamine triethiodide) is a nondepolarizing neuromuscular blocking agent that competitively antagonizes acetylcholine at nicotinic receptors at the neuromuscular junction, preventing muscle contraction.
Competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, blocking acetylcholine binding and inhibiting neuromuscular transmission, resulting in skeletal muscle paralysis.
0.08-0.12 mg/kg IV bolus for neuromuscular blockade; additional doses of 0.01-0.02 mg/kg as needed.
0.15-0.2 mg/kg IV bolus for intubation; maintenance: 1.5-2 mcg/kg/min IV infusion
None Documented
None Documented
The terminal elimination half-life of gallamine is approximately 2-4 hours in patients with normal renal function. This half-life is inversely related to creatinine clearance, and may be prolonged to 12-24 hours or more in patients with renal impairment, leading to cumulative effects and prolonged neuromuscular blockade.
Terminal elimination half-life is approximately 20-30 minutes (mean 24 minutes) in patients with normal renal and hepatic function; clinically, this short half-life supports rapid recovery after discontinuation and suitability for continuous infusion.
Flaxedil (gallamine triethiodide) is excreted primarily unchanged by the kidneys via glomerular filtration. Approximately 90-95% of an administered dose is eliminated in urine within 24 hours, with the remainder excreted in feces (<5%) via biliary elimination.
Primarily via Hofmann elimination (approximately 80%) and ester hydrolysis by nonspecific plasma esterases; renal excretion of unchanged drug accounts for less than 5% of the dose, and biliary/fecal elimination is minimal (less than 1%).
Category C
Category C
Neuromuscular Blocking Agent
Neuromuscular Blocking Agent